Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs

Documenti analoghi

• Brand vs. generic adverse event reporting patterns: an authorized generic-controlled evaluation of cardiovascular medications
  di: Alatawi, Yasser, et al.
  Pubblicazione: (2017)
• Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  di: Rahman, Md. Motiur, et al.
  Pubblicazione: (2017)
• Comparison of Brand versus Generic Antiepileptic Drug Adverse Event Reporting Rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  di: Rahman, Md. Motiur, et al.
  Pubblicazione: (2017)
• Comparison of generic-to-brand switchback patterns for generic and authorized generic drugs
  di: Hansen, Richard A., et al.
  Pubblicazione: (2017)
• Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug
  di: Hansen, Richard A., et al.
  Pubblicazione: (2017)